Who is really afraid of the TRIPS agreement? 

India has not shown the grit to fully use the inbuilt flexibilities in the WTO’s TRIPS pact to protect public health

Will a new and ‘improved’ WTO be in India’s interests

The World Trade Organization needs an overhaul, but the reform will leave even less space for developing nations

Bankruptcy of ideas and innovation: What India’s recent science & tech indicators show

Indians have shown little innovation over the decades. They are content to copy successful ideas from elsewhere or …

US officials urge to override Gilead patent

Most of US state attorney generals want the government to use its march-in-rights to license remdesivir to others

Remdesivir: Predatory pricing of an unproven drug

Gilead Science’s price for the remdesivir drug reveals a faulty patents system and skewed policies of the United States

Industry paid for IP seminars to train judges

Microsoft and Indian Music Industry funded FICCI to hold roundtable for Maharashtra judiciary; judges handling piracy cases special invitees

Dangers of a nationalist vaccine

In the time of COVID-19, the Indian government has shown an embarrassing readiness to cut corners by seeking to push through a vaccination by …

Smoke and mirrors on COVID-19 drugs?

In a brutal fight to corner the successful outcome of research, governments are openly using money power to grab the first rights to promising …

A promise of equitable access to all

WHO, pharma giants and governments have come together to provide access to all on COVID-19 therapies. But will WIPO allow this to happen?

A dirty US fight to control WIPO

China loses to Singapore in American smear campaign but the US will have to contend with an IP powerhouse

India’s proposed rules to curb web content to undercut digital freedom, privacy

Changes envisaged are far-reaching, making intermediaries accountable for content on their platforms; no longer eligible for safe harbour …

The great coronavirus drug hunt

A patent filed by Institute of Virology in Wuhan on cocktail of remdesivir and chloroquine raises some prickly questions 

ट्रंप का भारत दौरा: यह समझौता हुआ तो खत्म हो जाएगा सस्ती दवाओं का दौर

अमेरिकी राष्ट्रपति के भारत दौरे पर उनकी बौद्धिक संपदाओ�…

Beware of a deal with Trump

As the US president comes visiting to India there is worry about the demands he will make on intellectual property

The US takes on a drug giant

The US government's patent lawsuit against Gilead Sciences indicates it is tired of being milked by pharma companies

A Modi motto on innovation

A simplistic formulation ignores the reality of India's research environment and the constraint it faces

Cipla shows the way, again

The pioneer of inexpensive AIDS drugs made a paediatric medicine that will save thousands of children

India's withdrawal from RCEP a breather on many fronts

India's decision to pull out of RCEP means its policy on access to inexpensive drugs will not be under pressure

The problem for biosimilars

Reliance Life Sciences won a case against Roche, 4 years after the MNC sued to stave off challenge to a hit breast cancer drug

Encouraging orphan drugs in India

India needs to formulate an atrractive law to spur development of drugs for rare diseases

कम नहीं हुआ है बीज के अधिकार पर मंडराता खतरा

अमेरिकी कंपनी पेप्सिको और गुजरात के आलू उत्पादकों के बी…

WTO's assault on India

The US has serious problems with India, mostly related to programmes providing a lifeline to vulnerable farmers and ensuring food security of …

No end to these silly GIs

In their mad rush for Geographical Indication tags Indians are ignoring economic rationale

China’s intellectual property revolution

China saw an amazing transformation from a copycat nation, which was a byword for piracy, into a powerhouse of innovation

Risks associated with Artificial Intelligence worrying

And yet the concerns have not cast their shadow over India since AI research is still in its infancy in the country